PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
686.38%
Some net income increase while CRON.TO is negative at -149.70%. John Neff would see a short-term edge over the struggling competitor.
40.15%
D&A growth well above CRON.TO's 73.74%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-25.81%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
310.60%
SBC growth well above CRON.TO's 11.53%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-602.02%
Both reduce yoy usage, with CRON.TO at -237.82%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-138.18%
Both yoy AR lines negative, with CRON.TO at -83.31%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-144.96%
Negative yoy inventory while CRON.TO is 70.28%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-100.00%
Both negative yoy AP, with CRON.TO at -255.25%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-19.42%
Both reduce yoy usage, with CRON.TO at -191.36%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-330.67%
Negative yoy while CRON.TO is 87.82%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-12852.71%
Both yoy CFO lines are negative, with CRON.TO at -436.96%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
18.60%
Lower CapEx growth vs. CRON.TO's 70.16%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
649.13%
Some acquisitions while CRON.TO is negative at -547.66%. John Neff sees competitor possibly pausing M&A or divesting while the firm invests in new deals.
87.28%
Some yoy expansion while CRON.TO is negative at -451.30%. John Neff sees competitor possibly refraining from new investments or liquidating existing ones for immediate cash.
18.93%
We have some liquidation growth while CRON.TO is negative at -88.17%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
-973.07%
Both yoy lines negative, with CRON.TO at -2262.30%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
62.56%
Investing outflow well above CRON.TO's 59.67%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-43.37%
We cut debt repayment yoy while CRON.TO is 76.87%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.00%
Negative yoy issuance while CRON.TO is 127.96%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40